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The transcriptional coactivator peroxisome 
proliferator-activated receptor γ 
coactivator 1α (PGC-1α) is a key integrator 
of neuromuscular activity in skeletal muscle. 
Ectopic expression of PGC-1α in muscle 
results in increased mitochondrial number 
and function as well as an increase in 
oxidative, fatigue-resistant muscle fibers. 
Whole body PGC-1α knockout mice have a 
very complex phenotype, but do not have a 
marked skeletal muscle phenotype. We thus 
analyzed skeletal muscle-specific PGC-1α 
knockout mice to identify a specific role for 
PGC-1α in skeletal muscle function. These 
mice exhibit a shift from oxidative type I 
and IIa towards type IIx and IIb muscle 
fibers. Moreover, skeletal muscle-specific 
PGC-1α knockout animals have reduced 
endurance capacity and exhibit fiber 
damage and elevated markers of 
inflammation following treadmill running. 
Our data demonstrate a critical role for 
PGC-1α in maintenance of normal fiber 
type composition and of muscle fiber 
integrity following exertion. 
 
Skeletal muscle has an enormous capacity to 
adapt to motor neuron activity. Many changes 
in gene expression are controlled by motor 
neuron-induced calcium signaling (1-3). The 
transcriptional coactivator peroxisome 
proliferator-activated receptor γ coactivator 1α 
(PGC-1α) is at the nexus of this signaling and 
subsequently regulates the expression of gene 
programs needed for skeletal muscle 
adaptations to increased work load (4,5). By 
coactivating the myocyte enhancer factor 2 
members MEF2C and MEF2D, PGC-1α 
potently drives transcription of myofibrillar 
genes typical of oxidative muscle fibers (6). 
Interestingly, MEF2 and PGC-1α also control 
PGC-1α gene transcription in an 
autoregulatory loop (7,8). Metabolic genes, 
including those responsible for mitochondrial 
oxidative phosphorylation (OXPHOS), are 
induced by a transcriptional cascade with 
coactivation of the estrogen-related receptor α 
(ERRα, official nomenclature NR3B1), the 
nuclear respiratory factor 2 (NRF-2, 
alternatively called GA-binding protein, 
GABP) and the nuclear respiratory factor 1 
(NRF-1) by PGC-1α and subsequent increase 
in the levels of mitochondrial transcription 
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factor A (TFAM), and mitochondrial 
transcription specificity factors TFB1M and 
TFB2M (9-13). Recently, we have found that 
activity-induced remodeling of the 
postsynaptic side of neuromuscular junctions 
involves a complex between PGC-1α, GABP 
and host cell factor (HCF) that assembles upon 
phosphorylation of PGC-1α and GABP in 
post-synaptic nuclei (14). 
 
Data obtained from muscle-specific PGC-1α 
transgenic animals underline the importance of 
PGC-1α in skeletal muscle in vivo (6). These 
mice have increased number and function of 
mitochondria accompanied by a higher 
number of type IIa and type I oxidative, slow 
twitch, high endurance muscle fibers (6). 
Furthermore, even in the absence of functional 
motor nerve signaling following hind leg 
denervation, ectopically expressed PGC-1α 
maintains skeletal muscle function and blunts 
skeletal muscle atrophy that normally occurs 
in the absence of motor neuron signaling (15). 
Thus, PGC-1α apparently controls most if not 
all of the transcriptional changes induced by 
motor neuron signaling in skeletal muscle. 
Surprisingly, whole body PGC-1α knockout 
animals do not exhibit a marked skeletal 
muscle phenotype (16). Despite a significant 
reduction of transcription of several 
mitochondrial genes, no difference in the 
relative numbers of the different fiber types is 
observed (17). However, whole body PGC-1α 
knockout animals have a dominant CNS 
phenotype that might mask the effects of loss-
of-function of PGC-1α in peripheral tissues 
(16). These mice are hyperactive, show 
circadian abnormalities and have 
constitutively activated AMP-activated kinase 
(AMPK) in skeletal muscle, all of which 
might compensate for the loss of PGC-1α in 
this tissue (16,18). In the liver, gluconeogenic 
and heme biosynthetic genes are constitutively 
elevated in whole body PGC-1α knockout 
animals even in the fed state (16). In contrast, 
and as expected from previous studies, fasting 
induction of gluconeogenic and heme 
biosynthetic genes is severely blunted in the 
liver of liver-specific PGC-1α knockout 
animals (19). 
 
To clarify the genetic requirement for PGC-1α 
in skeletal muscle function without the 
confounding variables seen in the whole body 
knockouts, skeletal muscle-specific PGC-1α 
knockout animals (MKOs) were generated 
(Handschin et al., manuscript in preparation). 
Here, we report a moderate reduction in the 
number of oxidative type I and type IIa muscle 
fibers and exercise capacity in these mice. 
Strikingly, skeletal muscle of MKOs have a 
low level of damaged and regenerating fibers. 
This compromised skeletal muscle integrity is 
dramatically exacerbated by physical exercise 
and accompanied by elevated markers of 
systemic inflammation. Our data thus 
highlight the importance of PGC-1α in 
maintaining proper function and integrity of 
skeletal muscle. 
 
EXPERIMENTAL PROCEDURES 
 
Animal experimentation. Generation of MKOs 
has been described elsewhere (Handschin et 
al., manuscript in preparation). Mice were held 
under standard conditions. All experiments 
and protocols were performed in accordance 
with the respective Animal Facility 
Institutional Animal Care and Use Committee 
regulations. 
Gene expression analysis. Total RNA was 
isolated from tissues using the Trizol reagent 
(Gibco) according to the manufacturer’s 
instructions. After DNase I digest, 1 μg of 
total RNA was reverse transcribed and 
analyzed using an Applied Biosystems Real-
Time PCR System 7300 using the ΔΔCt 
method. Relative gene expression was 
normalized to 18S rRNA levels. 
Histology. Tissues were dissected, embedded 
in OCT compound (VWR), dehydrated, 
embedded in paraffin and sectioned. The 
sections were subsequently stained with 
haematoxilin and eosin (H&E). Evans blue 
dye (1% solution) was i.p. injected at a 
concentration of 1% volume per bodyweight 
16 hours before the treadmill exercise. Mice 
were sacrificed pre- and 30 minutes post-
exercise, respectively and skeletal muscle 
frozen histological sections prepared. Evans 
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blue incorporation was analyzed by 
fluorescence microscopy. Evans blue-
penetrated muscle fibers and fibers with 
centrally located nuclei were counted in 20 
randomly chosen sections in blinded fashion 
and were normalized by the total number of 
muscle fibers per field. Immunofluorescent 
staining for type I, type IIa and type IIb 
muscle fibers was performed with antibodies 
against the respective myosin heavy chains as 
described (20). The relative number of the 
different fiber types were quantified by 
counting 20 sections of each muscle bed (type 
I: red, type IIa: blue, type IIx: black, type IIb: 
green). 
Comprehensive laboratory animal monitoring 
system (CLAMS). CLAMS (Columbia 
Instruments) analysis was performed for four 
light and three dark periods after an 
acclimatization of two days. Data about 
locomotive activity was collected every 48 
minutes on 16 mice simultaneously. 
Grip strength. Grip strength was assessed by 
an inverted screen test as described (21). Each 
mouse was placed on top of an elevated wire 
mesh grid, the screen was inverted and the 
animals timed until release from the grid. A 
maximum score of 60 seconds was given if the 
animal did not fall. 
Treadmill exercise. For 3 days, animals were 
acclimatized to treadmill running (Columbus 
Instruments) for 5 min at a speed of 10 m/min 
and on a 0% grade. One day before the 
treadmill experiment, animals were injected a 
1% Evans blue dye solution. The next day, 
animals ran on a treadmill tilted 10% uphill 
starting at a speed of 10 m/min for 5 min. 
Every subsequent 2 min, the speed was 
increased by 2 m/min until mice were 
exhausted or a maximal speed of 46 m/min 
was reached (Supplemental Fig. S1). 
Exhaustion was defined as the inability of the 
animal to remain on the treadmill despite an 
air puff stimulus and mechanical prodding. 
Running time was measured and running 
distance, work and power calculated. Distance 
is a function of time and speed of the treadmill. 
Work is calculated as the product of 
bodyweight (kg), gravity (9.81 m/s2), vertical 
speed (m/s * angle) and time (s). Power is the 
product of bodyweight (kg), gravity (9.81 
m/s2) and vertical speed (m/s * angle). 
Determination of TNFα serum concentration. 
Serum TNFα was determined from mouse 
serum using a Quantikine Mouse TNFα 
ELISA kit, respectively, according to the 
manufacturer’s instructions (R&D Systems). 
Serum creatine kinase assay. Mouse blood 
was collected and serum isolated using 
heparin-coated collection tubes (BD 
Biosciences). Serum creatine kinase activity 
was then determined with the Creatine Kinase-
SL Assay Kit according to the manufacturers 
protocol (Diagnostic Chemicals Limited). 
Denervation, determination of muscle mass. 
Disuse atrophy was induced by surgical 
ablation of the sciatic nerve on one hind-leg as 
described (15). Muscle mass of the control leg 
and the denervated leg was determined 12 
days after the surgery. 
Statistical analysis. All results are expressed 
as means and error bars depict standard errors. 
Two-tailed Student’s t-test was used to 
determine p values. Statistical significance 
was defined as p<0.05. For all experiments, at 
least 8 mice per group were used. 
 
RESULTS 
 
Muscle-specific knockout animals of PGC-1α 
(MKOs) have an increased number of 
glycolytic myofibers. The generation of the 
MKOs of PGC-1α and analysis of mRNA and 
protein expression has been described 
elsewhere (Handschin et al., manuscript in 
preparation). These animals have a reduced 
expression of number of mitochondrial genes 
(Fig. 1) that were previously found to be 
elevated in PGC-1α muscle transgenic mice 
(15). Interestingly, PGC-1β levels are not 
altered by PGC-1α ablation in skeletal muscle 
as a compensatory mechanism (Fig. 1). 
Mitochondrial gene expression and oxidative 
metabolism are hallmarks of the slow-twitch, 
oxidative type I and IIa myofiber (3). Thus, to 
study if the corresponding myofibrillar gene 
expression is also altered in MKOs compared 
to controls, we measured the relative gene 
expression levels of the respective myosin 
heavy chain (MyHC) isoforms I, IIa, IIx and 
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IIb in gastrocnemius by semiquantitative real-
time PCR comparing control to MKO mice. 
Transcript levels for MyHCI and MyHCIIa 
were lower in MKOs vs. control animals, 
being reduced by 47% and 78%, respectively 
(Fig. 2A). In contrast, MKOs had significantly 
higher expression of MyHCIIx (+22% vs. 
controls) and MyHCIIb (+29% vs. controls) 
(Fig. 2A) indicating a reduction in oxidative, 
high endurance fibers and an increase in fast-
twitch, glycolytic fibers in MKOs. These 
findings were consistent with histological 
analysis of different muscle beds (Fig. 2B and 
Supplemental Fig. S1). Type IIa fibers were 
predominantly replaced by type IIb fibers in 
gastrocnemius, plantaris and tibialis anterior, 
In MKO soleus muscle, a muscle rich in type I 
and IIa fibers, type I and type IIa fibers were 
both reduced by 11% and 45%, respectively, 
and a clear increase in type IIb fibers was 
observed (+10%) (Fig. 2B and Supplemental 
Fig. S1). In control animals, type IIb fibers 
were very rarely found in soleus (Fig. 2B). 
Thus, both in terms of gene expression and 
histology of myofibrillar proteins, skeletal 
muscles of MKOs have a higher percentage of 
the glycolytic IIx and IIb fibers at the apparent 
expense of a loss of oxidative type I and IIa 
fibers (Fig. 2 and Supplemental Fig. S1). 
Notably, the loss in type IIa fibers exceeds the 
reduction in type I fibers. In fact, a significant 
reduction of type I fibers was only observed in 
the gastrocnemius and the soleus whereas the 
number of type IIa fibers was lower in all four 
muscles. Interestingly, muscle-specific PGC-
1α transgenic animals show a greater increase 
in type IIa than type I fibers (6), thus 
providing a mirror image of the data obtained 
in MKOs. 
 
Reduced muscle function and exercise 
capacity in MKOs. Ectopic expression of 
PGC-1α in skeletal muscle resulted a higher 
fatigue resistance ex vivo in isolated muscle 
fibers (6). Accordingly, PGC-1α levels in 
muscle correlate with the degree of physical 
activity: PGC-1α transcription is induced by 
exercise and repressed by disuse (15,22). To 
study the impact of PGC-1α ablation on 
skeletal muscle function in intact animals, we 
assessed the physical condition of MKOs and 
control animals. Monitoring of locomotive 
activity in comprehensive laboratory animal 
monitoring systems (CLAMS) revealed that 
MKOs have regular circadian rhythms in 
terms of physical activity (Fig. 3A). However, 
MKOs are hypoactive as compared to control 
mice (Fig. 3A and B). These findings are in 
stark contrast to the hyperactive PGC-1α total 
knockout animals (16). Interestingly, the 
decrease in physical activity in MKOs is 
similar in the light and the dark period (Fig. 
3B). The hyperactivity of PGC-1α total 
knockout mice was predominantly caused by 
abnormal activity during the light period (16). 
Thus, voluntary physical activity is uniformly 
reduced in the light and dark phases in MKO 
mice. 
 
In addition to spontaneous muscle usage, we 
challenged control and MKO animals with 
involuntary physical exercise testing muscle 
endurance. First, muscle grip strength was 
tested using an inverted screen. Inverted 
screen tests for muscle grip strength 
predominantly measure isometric muscle 
endurance. Previous analyses showed a 
decreased performance of global PGC-1α 
knockout mice in this type of test (21). But 
because of the various abnormalities in global 
PGC-1α knockouts, we decided to reassess 
this in the MKOs. MKO mice showed 
compromised muscle function compared to the 
control mice in this assay (Fig. 3C). In the two 
trials, MKOs were able to hold on for an 
average of 17 and 16 seconds, respectively, 
whereas control mice dropped after 42 and 45 
seconds, respectively (Fig. 3C). Thus, lack of 
skeletal muscle PGC-1α leads to a 60% 
reduction in grip strength performance in 
MKOs. Previously published results of PGC-
1α total knockout animals in the inverted 
screen test (21) can now be conclusively 
explained by impaired muscle function. 
 
Muscle endurance with dynamic fiber 
contractions was assessed by treadmill running 
to exhaustion, as an indicator of maximal 
muscle capacity. After acclimatization, mice 
were run on a 10% slope with a protocol using 
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increasing speed (Supplemental Fig. S2) until 
the animals were unable to remain on the 
treadmill despite air puff stimuli and prodding. 
Control animals ran roughly 7.5 minutes 
(28%) longer than MKOs, an average of 26 
minutes and 52 seconds for the controls vs. 19 
minutes and 25 seconds for the MKOs (Fig. 
3D). The difference in running distance was 
even bigger because of the running protocol 
with increasing speed (Fig. 3E). While MKOs 
covered an average distance of 323 meters, 
control mice ran 536 meters on the average (a 
difference of 40%). Finally, work and power 
generated by control animals were also higher 
than those of MKOs (Fig. 3F and 3G). Control 
mice used energy equivalent to 1007 J 
whereas the average work of MKOs came to 
594 J (a difference of 41%). Finally, the 17.3 
mW of power of the control mice are 25% 
higher than the 13.1 mW of the MKOs. In 
summary, all the parameters obtained from the 
treadmill running experiment describing 
muscle endurance were significantly lower for 
MKOs compared to control mice. Thus, the 
decrease in muscle function in MKOs could 
consistently be shown in different tests 
assessing voluntary physical activity, 
isometric and dynamic muscle endurance. 
Interestingly, PGC-1α total knockout animals 
performed even worse than MKOs in treadmill 
running (21). This might reflect additional 
defects in heart function and the motor neuron 
system in whole body PGC-1α knockout mice 
that also contribute to physical endurance. 
 
Basal and exercise-induced myopathy in 
MKOs. Muscle contraction exerts mechanical 
stress on muscle fibers. Excess stress can lead 
to muscle damage that is normally offset by 
muscle regeneration. As described above, 
MKOs have a diminished capacity for 
physical movement, both voluntary and forced. 
In haematoxilin & eosin (H&E) staining of 
cross-sections of quadriceps, a higher number 
of muscle fibers with centrally located nuclei, 
a hallmark of regenerating muscle fibers, is 
found in MKOs compared to control mice (Fig. 
4A). We thus checked the expression of 
various markers of muscle damage and 
regeneration to study the impact of muscle-
specific PGC-1α ablation on muscle fiber 
integrity. Interestingly, we observed a massive 
induction of Pax7 gene expression in MKOs 
(Fig. 4B), a molecular marker for satellite cells 
(23). In the MKOs, myogenin expression was 
not significantly decreased. Future studies will 
address this discrepancy between the 
published reciprocal regulation between Pax7 
and the other muscle regulatory factors in cell 
culture (24) and our data in vivo. In addition 
to Pax7, transcript levels of MyHC3, normally 
only observed in embryonic stages of muscle 
development, were elevated in MKOs 
compared to control animals (Fig. 4B). 
Together, these data suggest that muscle fiber 
regeneration is induced in MKOs by increased 
recruitment of satellite cells and the transient 
expression of MyHC3 in newly formed 
muscle fibers. Elevated markers for cell 
proliferation and decreased levels of genes 
involved in growth arrest support this 
hypothesis (Supplemental Fig. S3). Increased 
muscle fiber regeneration is often a sign of 
muscle damage in mice, and muscle damage 
leads to higher serum creatine kinase levels in 
the blood leaking from muscle fibers. We 
therefore measured serum creatine kinase 
activity in pre- and post-exercise control and 
MKO animals, respectively. We found a three-
fold increase in serum creatine kinase in 
sedentary MKOs compared to controls (Fig. 
4C). Creatine kinase levels were further 
elevated by exercise in MKOs (Fig. 4C). To 
estimate the degree of muscle damage in 
MKOs, we i.p. injected Evans blue dye into 
control and MKO animals pre- and post-
exercise. Evans blue can penetrate damaged 
muscle fibers and is visualized by fluorescent 
microscopy of histological sections (e.g., see 
ref. (14)) The increased staining of muscle 
fibers in pre-exercise MKOs vs. control 
animals (Fig. 4D) indicated that MKOs exhibit 
a low grade muscle damage, even in the basal 
state. The number of Evans blue positive 
muscle fibers was clearly increased in MKOs 
post exercise (Fig. 4D). In comparison, control 
animals have no visible muscle fiber damage 
after treadmill running (Fig. 4D). Thus, 
skeletal muscle PGC-1α is required in 
maintaining muscle fiber integrity in the 
sedentary state; this is even more so during 
and following physical exertion. 
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Increased inflammatory response in sedentary 
and exercised MKOs. Many different 
mechanisms could be involved in the muscle 
damage observed in MKOs. Idiopathic 
inflammatory myopathies are well described 
disease pathologies in human patients, and 
tumor necrosis factor α (TNFα) has been 
causally implicated in this process (25).We 
previously noted increased expression of 
different inflammatory markers in MKO 
skeletal muscle in a non-exercised state, 
including elevated mRNA levels for 
interleukin 6 (IL-6) and TNFα (Handschin et 
al., manuscript in preparation). In addition, 
circulating IL-6 levels in the blood were 
elevated in MKOs compared to controls, but 
we did not see a significant difference in 
circulating TNFα levels in the non-exercised 
context. To investigate whether elevation of 
TNFα could be involved in the increase in 
muscle damage post-exercise, we measured 
gene expression levels and circulating 
concentrations of TNFα in mice after 
treadmill running. In MKOs, TNFα gene 
expression was higher both pre- and post-
exercise compared to control mice (Handschin 
et al., manuscript in preparation and Fig. 5A). 
Remarkably, transcript levels of TNFα were 
massively increased in exercised MKOs 
compared to pre-exercised MKOs, whereas no 
change in TNFα expression was observed in 
control mice before and after physical activity 
(Fig. 5A). This increase in gene expression 
was paralleled by a marked rise in circulating 
TNFα in the blood of MKOs (Fig. 5B). In fact, 
in sedentary MKOs and sedentary or exercised 
control animals, circulating TNFα levels were 
below the detection limit of our assay and we 
could only detected circulating TNFα in 
exercised MKOs. Thus, increased cytokine 
levels, in particular those for TNFα in MKOs 
likely contribute to the fiber damage by 
inducing an inflammatory myopathy. 
 
DISCUSSION 
 
Gain-of-function studies in vitro and in vivo 
established the importance of PGC-1α in 
skeletal muscle. Unfortunately, the complex 
phenotype of the whole body knockout of 
PGC-1α that included hyperactivity 
confounded, to a great extent, analysis of 
skeletal muscle structure and function in these 
animals. In the skeletal muscle-specific PGC-
1α knockout animal model studied here, we 
now conclusively show that PGC-1α is 
required for the maintenance of a normal 
number of oxidative type I and type IIa muscle 
fibers. Accordingly, PGC-1α MKO mice are 
not able to match physical performance of 
control animals. This was shown for voluntary 
physical activity, forced isometric muscle 
endurance in grip strength tests and dynamic 
muscle endurance in treadmill running. In 
addition to their distinct functions, PGC-1α 
and PGC-1β share common protein binding 
partners and the regulation of certain gene 
programs in skeletal muscle (4,5). It is thus 
conceivable that PGC-1β could at least 
partially compensate for the lack of PGC-1α. 
However, no compensatory regulation of 
PGC-1β gene expression in skeletal muscle of 
MKOs was observed. 
 
A surprising finding was that mice with a 
specific ablation of PGC-1α in skeletal muscle 
have increased signs of muscle fiber damage 
and regeneration. Under basal conditions, this 
damage does not lead to reduced muscle 
weight (Supplemental Fig. S4A). Despite the 
protection observed in PGC-1α muscle 
transgenic animals against denervation-
induced muscle atrophy, MKOs show no 
increased propensity for disuse-mediated 
muscle atrophy (Supplementary Fig. S4A). 
Accordingly, expression of atrogenes that 
control muscle atrophy are not elevated 
(Supplemental Fig. S4B). Interestingly, the 
muscle injury in MKOs is dramatically 
exacerbated by physical activity. Different 
factors could contribute to the muscle 
pathology in MKOs. First, these animals have 
a reduction in mitochondrial gene expression. 
Mitochondrial dysfunction is associated with 
muscle damage in Duchenne muscular 
dystrophy (26,27). Second, reactive oxygen 
species (ROS) detoxification is crucially 
regulated by PGC-1α (28) and the levels of a 
number of ROS detoxification genes are 
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reduced in MKOs, including superoxide 
dismutase 1, superoxide dismutase 2, adenine 
nucleotide transporter and glutathione 
peroxidase 1 (14). ROS cause membrane and 
protein modifications and have been causally 
linked to muscle damage (29). In addition, we 
recently found that PGC-1α regulates the gene 
program involved in postsynaptic 
neuromuscular junction plasticity (14). MKOs 
have a lower number of acetylcholine clusters 
on muscle fiber membranes (14) and thus 
might be insufficiently innervated. Finally, 
systemic inflammation, acute and chronic, is a 
strong promoter of skeletal muscle wasting. In 
MKOs, we observed increased levels of 
circulating cytokines IL-6 and TNFα. In 
particular, the rise in plasma TNFα levels 
paralleled the dramatic increase in muscle 
fiber damage post exercise. TNFα is known to 
cause inflammatory myopathies in rodent 
models and human patients (30,31). Our 
hypothesis that increased systemic 
inflammation in MKOs might contribute to the 
myopathy is supported by other physiological 
and behavioral abnormalities in these mice. 
The decrease in body weight and fat mass, 
reduced physical activity, skeletal muscle 
damage, increased body temperature and basal 
metabolic rate and diminished food intake 
(Handschin et al., manuscript in preparation) 
are compatible with symptoms observed in 
animal models and human patients suffering 
from chronic inflammation. 
 
In summary, our findings both confirm data 
obtained from gain-of-function experimental 
models and provide novel, surprising insights 
into the function of PGC-1α in skeletal muscle. 
The results highlight the central role for PGC-
1α to integrate motor neuron input and 
regulate gene programs involved in oxidative 
fiber type determination and muscle fiber 
endurance. Further more, our data also show 
that PGC-1α is important for maintaining 
skeletal muscle fiber integrity, especially after 
physical stress. The observation of 
inflammatory myopathy and overall signs of 
chronic inflammation in MKOs open novel 
avenues in our understanding of these 
devastating muscle diseases and might result 
in alternative ways of preventing and treating 
skeletal muscle dysfunctions. 
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FIGURE LEGENDS 
 
Fig. 1. Decreased metabolic gene expression in MKOs. Relative gene expression was measured from 
cDNA extracted from gastrocnemius and normalized to 18S rRNA levels. Bars depict mean values and 
error bars represent standard error. *p<0.05 between control and MKO animals. Abbreviations: PDH: 
pyruvate dehydrogenase β; MCAD: medium chain acyl-CoA dehydrogenase; PGAM1: phosphoglycerate 
mutase 1; PDC-E2: pyruvate dehydrogenase complex, E2 component; MDH1: malate dehydrogenase 1, 
NAD (soluble); OXCT1: 3-oxoacid CoA transferase; CKMT2: creatine kinase, mitochondrial 2 
(sarcomeric); LDHA: lactate dehydrogenase A. 
 
Fig. 2. Fiber-type switching towards increased numbers of glycolytic fibers in MKOs. A, Relative 
gene expression was measured from cDNA extracted from gastrocnemius and normalized to 18S rRNA 
levels. B, Cross-sections of plantaris, tibialis anterior and soleus were immunostained for myosin heavy 
chains I (red), IIa (blue) and IIb (green). Bars depict mean values and error bars represent standard error. 
*p<0.05 between control and MKO animals. 
 
Fig. 3. Decreased physical activity and impaired muscle function in MKOs. A, Circadian patterns of 
voluntary locomotive activity were recorded for 4 light and 3 dark periods in comprehensive laboratory 
animal monitoring systems by infrared beam breaking. B, Average locomotive activity of control mice 
and MKOs. C, Grip strength tests assessed the ability of control and MKO animals to hold onto an 
inverted grid wire mesh. A maximal score of 60 s was assigned to mice that did not fall down. Trial 2 was 
repeated 30 min after Trial 1. D, E, F, G, Treadmill exercise. After acclimatization, mice were run on a 
treadmill with a 10% slope and increasing speed to exhaustion. Time (panel D), distance (panel E), work 
(panel F) and power (panel G) were calculated from the individual performances. Bars depict mean values 
and error bars represent standard error. *p<0.05 between control and MKO animals. 
 
Fig. 4. MKOs have damaged muscle fibers. A, Haematoxilin & eosin (H&E) staining of gastrocnemius 
cross-sections. Arrowheads point to muscle fibers with centrally located nuclei. B, Relative gene 
expression measured from cDNA of gastrocnemius muscle and normalized to 18S rRNA levels. 
Abbreviations: Pax7, paired box gene 7; MyoD, myogenic differentiation antigen 1; Myf5, myogenic 
factor 5; MRF4, muscle regulator factor 4; MyHC, myosin heavy chain. C, Serum creatine kinase levels. 
Serum creatine kinase activity was determined in sedentary animals (pre-exercise) and mice that were 
sacked 30 min after the treadmill exercise (post-exercise). D, Evans blue dye was i.p. injected and mice 
sacked 16 h later. Post-exercise animals were analyzed 30 min after completion of the treadmill running. 
Bars depict mean values and error bars represent standard error. *p<0.05 between control and MKO 
animals. 
 
Fig. 5. Increased expression of TNFα in MKO skeletal muscle. A, Relative gene expression of TNFα 
normalized to 18S rRNA levels in control and MKO animals that were sedentary (pre-exercise) or 
exercised (post-exercise), respectively. B, Circulating TNFα concentration in control and MKO animals 
that were sedentary (pre-exercise) or exercised (post-exercise), respectively. Abbreviations: n.d., not 
detectable. Bars depict mean values and error bars represent standard error. *p<0.05 between control and 
MKO animals. 
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SUPPLEMENTAL FIGURES 
 
Supplemental Fig. S1. Fiber-type switch towards glycolytic fibers in MKOs. The relative number of 
muscle fibers were quantified by counting type I (red color), type IIa (blue color), type IIx (unstained, 
black color) and type IIb fibers (green color) in twenty histological sections of gastrocnemius (panel A), 
plantaris (panel B), tibialis anterior (panel C) and soleus (panel D). *p<0.05 between control and MKO 
animals. 
 
Supplemental Fig. S2. Treadmill running protocol. Control and MKO mice were run on a treadmill 
with increment increase in speed. Control mice performed significantly better than MKOs. 
 
Supplemental Fig. S3. Increased expression of markers for cell proliferation in PGC-1α MKOs. 
Relative gene expression from pooled mRNA of the gastrocnemius of 6 mice was analyzed by real-time 
PCR and normalized to 18S rRNA levels. Abbreviations: P/CAF: p300/CBP-associated factor; GST1: G1 
to S phase transition 1; UBE2: ubiquitine-conjugating enzyme E2 variant 2; MAPRE3: microtubule-
associated protein RP/EB Family Member 3; APC5: anaphase promoting complex subunit 5; PCNA: 
proliferating cell nuclear antigen; GADD45: growth arrest and DNA damage-inducible gene b; RBB4: 
retinoblastoma binding protein 4. 
 
Supplemental Fig. S4. No exacerbation of muscle atrophy by PGC-1α knockout. A, Relative gene 
expression of cDNA from gastrocnemius muscle and normalized to 18S rRNA levels. Abbreviations: 
IGF-1, insulin-like growth factor 1; MuRF-1, muscle-specific ring finger protein 1. B, Muscle weights 
from innervated and denervated hind legs. Disuse-mediated muscle atrophy was induced by surgical 
ablation of the sciatic nerve to one hind leg. Muscle mass was determined 12 days after hind leg 
denervation. Bars depict mean values and error bars represent standard error. *p<0.05 between control 
and MKO animals. 
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